After almost a decade, newer antiviral therapies are now available, providing hope to people with hepatitis C by improving the cure rate of the disease and shortening the duration of treatment.
Our team of specialists at the UPMC Center for Liver Diseases has been at the forefront of the evaluation process and clinical trials of these therapies.
Recently approved by the Food and Drug Administration (FDA), two direct-acting antiviral agents have been used to treat adult patients with chronic hepatitis C (genotype 1) viral infection.
Our liver disease experts also are actively conducting clinical trials of additional therapies to improve the care of people with hepatitis C.
While these results are promising, the management of these medications is quite complex. Patients require a multidisciplinary approach to achieve a successful outcome.
The team at the UPMC Center for Liver Diseases — all dedicated to the management of chronic hepatitis C — includes:
Our hepatologists’ experience with the use of these medications provides us with an optimal perspective for managing the complexities of these new therapies, while providing support to patients and their families.